Insider Selling: Alphatec Holdings, Inc. (NASDAQ:ATEC) COO Sells 36,081 Shares of Stock

Key Points

• Scott Lish, COO of Alphatec Holdings, Inc., sold 36,081 shares of the company on August 1st for a total transaction of $452,094.93, reducing his holdings by 4.84%.
• Alphatec reported a quarterly EPS of $0.02, beating analysts' expectations of negative earnings, with revenue reaching $185.54 million, a 27.5% increase from the previous year.
• Institutional investors currently own 66.35% of Alphatec's stock, with significant recent positioning changes from major funds like Bank of Montreal Can and Corton Capital Inc.

Alphatec Holdings, Inc. (NASDAQ:ATEC - Get Free Report) COO Scott Lish sold 36,081 shares of the company's stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $12.53, for a total transaction of $452,094.93. Following the completion of the sale, the chief operating officer directly owned 708,855 shares of the company's stock, valued at approximately $8,881,953.15. This represents a 4.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website.

Scott Lish also recently made the following trade(s):

• On Tuesday, August 5th, Scott Lish sold 16,666 shares of Alphatec stock. The stock was sold at an average price of $15.00, for a total value of $249,990.00.
• On Monday, August 4th, Scott Lish sold 17,857 shares of Alphatec stock. The stock was sold at an average price of $14.00, for a total transaction of $249,998.00.
• On Thursday, July 10th, Scott Lish sold 3,982 shares of Alphatec stock. The stock was sold at an average price of $12.00, for a total transaction of $47,784.00.
• On Friday, June 13th, Scott Lish sold 22,727 shares of Alphatec stock. The shares were sold at an average price of $11.07, for a total value of $251,587.89.
• On Monday, May 19th, Scott Lish sold 55,375 shares of Alphatec stock. The shares were sold at an average price of $13.00, for a total value of $719,875.00.

Alphatec Stock Performance

ATEC stock traded down $0.30 during mid-day trading on Thursday, reaching $14.90. 4,026,654 shares of the stock traded hands, compared to its average volume of 2,070,535. Alphatec Holdings, Inc. has a 52 week low of $4.88 and a 52 week high of $15.46. The company has a quick ratio of 1.77, a current ratio of 2.88 and a debt-to-equity ratio of 23.22. The firm has a market capitalization of $2.20 billion, a PE ratio of -13.19 and a beta of 1.05. The business has a 50-day moving average of $11.53 and a two-hundred day moving average of $11.23.

Alphatec (NASDAQ:ATEC - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The medical technology company reported $0.02 earnings per share for the quarter, beating the consensus estimate of ($0.06) by $0.08. The company had revenue of $185.54 million during the quarter, compared to analysts' expectations of $178.85 million. Alphatec had a negative return on equity of 1,657.19% and a negative net margin of 24.33%. Alphatec's revenue for the quarter was up 27.5% compared to the same quarter last year. During the same period in the prior year, the business earned ($0.29) earnings per share. As a group, equities analysts predict that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Institutional Investors Weigh In On Alphatec

A number of institutional investors have recently added to or reduced their stakes in the company. Connor Clark & Lunn Investment Management Ltd. increased its stake in Alphatec by 315.3% in the second quarter. Connor Clark & Lunn Investment Management Ltd. now owns 398,716 shares of the medical technology company's stock valued at $4,426,000 after acquiring an additional 302,718 shares during the period. Fox Run Management L.L.C. bought a new stake in shares of Alphatec in the 2nd quarter valued at approximately $471,000. Savant Capital LLC raised its holdings in shares of Alphatec by 18.8% in the 2nd quarter. Savant Capital LLC now owns 15,303 shares of the medical technology company's stock worth $170,000 after buying an additional 2,421 shares in the last quarter. Corton Capital Inc. lifted its position in shares of Alphatec by 36.3% during the 2nd quarter. Corton Capital Inc. now owns 19,157 shares of the medical technology company's stock worth $213,000 after buying an additional 5,097 shares during the period. Finally, Bank of Montreal Can boosted its stake in Alphatec by 545.7% in the 2nd quarter. Bank of Montreal Can now owns 743,041 shares of the medical technology company's stock valued at $8,248,000 after buying an additional 627,973 shares in the last quarter. 66.35% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research firms have recently issued reports on ATEC. HC Wainwright restated a "buy" rating and issued a $20.00 target price on shares of Alphatec in a report on Monday, April 14th. Lake Street Capital upgraded shares of Alphatec to a "buy" rating and set a $18.00 price target for the company in a report on Monday, June 16th. Needham & Company LLC reiterated a "buy" rating and issued a $16.00 price objective on shares of Alphatec in a research note on Friday, May 2nd. Barclays reissued an "overweight" rating and set a $22.00 target price (up previously from $21.00) on shares of Alphatec in a research note on Monday. Finally, Piper Sandler reaffirmed an "overweight" rating and issued a $15.00 price target (up from $13.00) on shares of Alphatec in a research note on Friday, May 2nd. One analyst has rated the stock with a hold rating and six have assigned a buy rating to the stock. Based on data from MarketBeat, Alphatec currently has a consensus rating of "Moderate Buy" and an average price target of $18.50.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.